Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 212 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Drowsiness Clear all
Terminated Not applicable Interventional Results available

Transcranial Direct Current Stimulation Therapy for Sleepiness Related to Shift Work Disorder (tDCS-SWORD)

NCT03879044
View directory record Official record
Conditions
Shift-Work Sleep Disorder
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

NCT06812078
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
TAK-360, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Redwood City, California • Santa Ana, California • Colorado Springs, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Enrolling by invitation No phase listed Observational

Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments

NCT05371483
View directory record Official record
Conditions
Narcolepsy, Idiopathic Hypersomnia
Interventions
24-hour Ambulatory Blood Pressure Monitoring, Oculo-Cognitive Addition Test (OCAT)
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease

NCT01742182
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Light exposure
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 23, 2026, 10:45 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia

NCT06644573
View directory record Official record
Conditions
Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder, REM Sleep Behavior Disorder, REM Sleep Measurement, Insomnia, Insomnia Related to Specified Disorder, Insomnia Due to Other Mental Disorder, Insomnia Comorbid to Psychiatric Disorder, Insomnia Due to Anxiety and Fear, Insomnia Related to Another Mental Condition, Insomnia Disorders, Idiopathic Hypersomnia, Sleep Disorders, Circadian Rhythm, Post Trauma Nightmares, PTSD - Post Traumatic Stress Disorder, Sleep Quality, Anesthesia, Anxiety, Depression, Mental Health, Alzheimer Disease or Associated Disorder, Parkinsons, Circadian Rhythm, Circadian Dysregulation, PTSD, Post-Traumatic, Post-Traumatic Stress Disorder Complex, Military Combat Stress Reaction, Sleep, Military Activity, Veterans, Shift Work Sleep Disorder, Menopause Related Conditions, Pain, Cancer Pain, Athletes
Interventions
PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca, Continuous EEG Monitoring
Procedure · Drug · Device
Lead sponsor
Nyree Penn
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Completed No phase listed Observational

A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy

NCT02769780
View directory record Official record
Conditions
Narcolepsy
Interventions
Not listed
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bonafide Sleep Supplement for Menopausal Women With Sleep Complaints

NCT07839312
View directory record Official record
Conditions
Sleep Disturbance
Interventions
S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium Glycinate
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Enrolling by invitation Phase 1 Interventional

Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis

NCT06261528
View directory record Official record
Conditions
Progressive Multiple Sclerosis
Interventions
Light therapy
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 4 Interventional

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

NCT01591551
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab (Tysabri)
Drug
Lead sponsor
Cornerstone Health Care, PA
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Patchogue, New York • High Point, North Carolina • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

NCT02348619
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
JZP-110
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Oceanside, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 3 Interventional

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06366464
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Pitolisant tablet, Placebo tablet
Drug · Other
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
6 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Plant-based Diet on Postprandial Sleepiness

NCT05706649
View directory record Official record
Conditions
Drowsiness
Interventions
Plant-based diet
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 23, 2026, 10:45 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The Nuvigil and Provigil Pregnancy Registry

NCT01792583
View directory record Official record
Conditions
Narcolepsy, Obstructive Sleep Apnea, Shift Work Sleep Disorder
Interventions
Modafinil/armodafinil
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
Female only
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
1
States / cities
West Chester, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

NCT03959189
View directory record Official record
Conditions
Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy
Interventions
ERX-963, Placebo
Drug
Lead sponsor
Expansion Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Palo Alto, California • Miami, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence

NCT01338649
View directory record Official record
Conditions
Parkinson's Disease, Sleep Disorder; Excessive Somnolence
Interventions
Bright Light Treatment (Sun Ray Sunbox SB-558), Dim red light (Sun Ray Sunbox SB-558)
Device
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 23, 2026, 10:45 AM EDT
Withdrawn Early Phase 1 Interventional

Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia

NCT03626727
View directory record Official record
Conditions
Hypersomnia, Narcolepsy, Traumatic Brain Injury
Interventions
Sodium Oxybate Oral Solution [Xyrem]
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 23, 2026, 10:45 AM EDT
Completed No phase listed Observational

Development and Validation of Pediatric Narcolepsy Patient Reported Outcomes Scale

NCT05373979
View directory record Official record
Conditions
Narcolepsy, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children

NCT01554527
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Child Behavior Disorders, Attention Deficit Disorder With Hyperactivity, Disorders of Excessive Somnolence
Interventions
CPAP treatment, No CPAP treatment
Procedure · Other
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

NCT07598708
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2
Interventions
cleminorexton, Placebo
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Brandon, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

NCT06170970
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis Fatigue
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Clarithromycin Mechanisms in Hypersomnia Syndromes

NCT04026958
View directory record Official record
Conditions
Narcolepsy Without Cataplexy, Idiopathic Hypersomnia, Narcolepsy With Cataplexy
Interventions
Clarithromycin, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study

NCT02037438
View directory record Official record
Conditions
Obstructive Sleep Apnea of Adult, Insomnia, Circadian Rhythm Sleep Disorder, Sleep Related Movement Disorders, Narcolepsy and Hypersomnia, Parasomnia
Interventions
CONV care for the diagnosis and treatment of sleep disorders, PCCM for the diagnosis and treatment of sleep disorders
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1,836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration

NCT05008341
View directory record Official record
Conditions
Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum
Interventions
Solriamfetol 150 mg Oral Tablet
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

NCT05875974
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy
Interventions
JZP258 (XYWAV)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 10:45 AM EDT